Bicycle Therapeutics (BCYC) Common Equity (2018 - 2026)

Bicycle Therapeutics (BCYC) has 9 years of Common Equity data on file, last reported at $510.3 million in Q2 2026.

• Quarterly Common Equity fell 23.72% year-over-year to $510.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $510.3 million (down 23.72% YoY) and the FY2025 annual result came in at $610.0 million, down 23.09% from the prior year.
• Common Equity retreated to $510.3 million in Q2 2026, from $554.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $873.8 million in Q2 2024 to a low of $220.1 million in Q2 2023.
• A 5-year average of $500.5 million and a median of $463.1 million in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2023 — Common Equity slipped 29.32% — and 2024, when it surged 297.01%.
• Tracing BCYC's Common Equity over 5 years: stood at $270.8 million in 2022, then surged by 36.98% to $370.9 million in 2023, then surged by 113.8% to $793.1 million in 2024, then declined by 23.09% to $610.0 million in 2025, then fell by 16.35% to $510.3 million in 2026.
• The last three Common Equity figures came in at $510.3 million (Q2 2026), $554.3 million (Q1 2026), and $610.0 million (Q4 2025), per Business Quant data.